Johann D Ringe
Overview
Explore the profile of Johann D Ringe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ringe J
Expert Rev Endocrinol Metab
. 2019 Feb;
1(1):15-24.
PMID: 30743765
Zoledronic acid is a potent bisphosphonate widely used to counteract cancer-related bone loss. Once-yearly or even less frequent doses may be an effective therapy for benign bone disorders and may...
2.
Ringe J, Kipshoven C
MMW Fortschr Med
. 2016 Jul;
153(Suppl 4):115-8.
PMID: 27370632
No abstract available.
3.
Cianferotti L, Cricelli C, Kanis J, Nuti R, Reginster J, Ringe J, et al.
Endocrine
. 2015 May;
50(1):12-26.
PMID: 25931412
Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation. These metabolites display different...
4.
Gluer C, Marin F, Ringe J, Hawkins F, Moricke R, Papaioannu N, et al.
J Bone Miner Res
. 2013 Jan;
28(6):1355-68.
PMID: 23322362
Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce. We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an...
5.
Ringe J
Scand J Clin Lab Invest Suppl
. 2012 Apr;
243:73-8.
PMID: 22536766
Vitamin D (cholecalciferol) is important for normal development and maintenance of the skeleton. The metabolites 25(OH)D and 1,25(OH)(2)D are not only important for treating rickets and osteomalacia but also for...
6.
Ringe J, Schafer S, Wimmer A, Giesecke T
Wien Klin Wochenschr
. 2011 Nov;
124(1-2):25-31.
PMID: 22045112
Objective: To determine the effect of a lower starting dose of OROS® hydromorphone compared with a higher starting dose. Design: Data from the first 15 days of treatment were compared...
7.
Zittermann A, von Helden R, Grant W, Kipshoven C, Ringe J
Dermatoendocrinol
. 2011 May;
1(6):300-6.
PMID: 21572875
Background: Inadequate vitamin D status is a worldwide problem. Evidence is accumulating that individuals with low vitamin D status have excess mortality rates. We calculated to which extent annual mortality...
8.
Ringe J, Schacht E, Dukas L, Mazor Z
Arzneimittelforschung
. 2011 Mar;
61(2):104-11.
PMID: 21428245
This is a preplanned subgroup analysis on 318 patients with glucocorticoid-induced osteoporosis (GIOP) from an open, prospective, multi-centered, uncontrolled study on a large cohort of elderly patients with a high...
9.
Schacht E, Ringe J
Arzneimittelforschung
. 2011 Mar;
61(1):40-54.
PMID: 21355445
Efficacy and safety of a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1...
10.
Eastell R, Vrijens B, Cahall D, Ringe J, Garnero P, Watts N
J Bone Miner Res
. 2011 Feb;
26(7):1662-9.
PMID: 21312265
Surrogate markers of fracture risk--bone turnover markers (BTMs) and bone mineral density (BMD)--can be used to monitor treatment response. We assessed whether changes in these markers greater than the least...